Member Info for Vertizea-Sun

The bien-pensant helping the less privileged. So uplifting.

Well done Wyn......give Richard Hughes a bell and tell him he's blown it. He'll be all ears.

I'd appreciate a link to the technical briefings on "Pre|Cision 2 and 3 delivery platforms"

Like a child on the back seat.....are we there yet?

Third time lucky. Not a good look.

Do you think Richard Hughes is stupid enough to climb on to the Titanic?

Indivior, which makes opioid addiction treatments, has announced plans to delist in London and focus solely on New York.

Indivior was spun out of Reckitt Benckiser, the British consumer goods giant known for Dettol and Durex, in 2014. A member of the FTSE 250, Indivior is best known for its drug Suboxone, which is used to treat addiction to opioids such as heroin.

https://www.telegraph.co.uk/business/2025/06/02/pharma-giant-indivior-joins-london-stock-market-exodus/

Truly a man-child.

"If you're going to reply, don't forget to ask why he didn't post on Friday."

He posted on another board:

Did I miss anything?

30 May 2025 16:42

Nice day biking in North Corfu.

Now, plough through the posts or a pre-dinner dip and beer.

It's a tough call.

Unless you have personal or immediate family experience of cancer treatment you have absolutely no idea how awful chemo can be. My eldest child and my youngest sibling did - one survived and one didn't - but both said they'd rather die than continue with the side effects. So the armchair oncologists telling you that "marginal" improvement in outcome isn't worth it is a fool.

More or less eliminating side-effects with FAP/pre|CISION® is a priceless bit of IP.....to both the patient and the investor.

"rampers". A pejorative term used by the thread's originator in his opening sentence. To be followed by his very own favourite...."pom-pom girls".

Among patients completing 35 cycles of pembrolizumab, the objective response rate was 86%, and the 3-year OS rate after completion was 71.9%.

So far....so good.

All well and good but it rather depends on how much HCRx will be charging to allow the participating company (Avacta) to borrow against its assets.

Thanks to RAH on X:

#AVCT finally lands a heavyweight, bringing much needed and long-sought commercial depth to its board in Richard Hughes.

“Experience in fundraising”

Yes, just a tad… Richard Hughes is responsible for over a third of all monies raised across AIM IPOs over the last seven years:

➡️ £17.5Bn gross total deal valuations;

➡️ £9.4Bn gross sell side deals advised on;

➡️ £5Bn equity raised.

One recent example from the above extensive list: November 2024 - raised £39.3m for Debenhams Group, despite pretax losses widening to £27.4m (from £9.1m a year earlier).

That placing took place at a premium to the share price and was significantly oversubscribed.

If you can land money for Debenhams Group (both at a premium - and - oversubscribed!) when the Chinese are selling direct to consumer, you can sell water to a well.

“Experience in scaling businesses”

In 2009, he acquired wound specialist, Crawford Healthcare for £700k. Crawford was sold to Acelity for £103m in 2018.

Acelity was eventually bought by 3M for $6.7Bn in 2019.

The 2018 sale achieved x147 return in 9 years. Suffice to say he knows how to scale businesses.

Not a pharma man - a money man - which is precisely what this company needs.

The market (and every broking house) will now be asking what this City veteran - who has never before sat as a director of a listed company - sees in order to encourage him to step onto a public board for the first time in 35 years.

https://x.com/RAH00084/status/1927610516194607372

" to utilizing my experience in both fundraising and the scaling of businesses":

That means no T/O.

Forward it to Simon Bennett.

Don't bother to bookmark it. There will be a repeat later in the day.

Exactly.

The product is too important for it not to happen. It's a life saver and all the principal people know it.

We'll hear before the 29th imho.

Don't forget Nasdaq is being investigated. CC has mentioned it twice and she probably doesn't do idle chit-chat.

I think you are splitting hairs:

"with multiple patients treated in this portion of the trial, which include three indications:"